Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
0.6700
-0.0200 (-2.90%)
Oct 16, 2025, 3:54 PM EDT
Brainstorm Cell Therapeutics Employees
Brainstorm Cell Therapeutics had 27 employees as of December 31, 2024. The number of employees decreased by 2 or -6.90% compared to the previous year.
Employees
27
Change (1Y)
-2
Growth (1Y)
-6.90%
Revenue / Employee
n/a
Profits / Employee
-$394,759
Market Cap
6.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27 | -2 | -6.90% |
| Dec 31, 2023 | 29 | -14 | -32.56% |
| Dec 31, 2022 | 43 | 0 | - |
| Dec 31, 2021 | 43 | 3 | 7.50% |
| Dec 31, 2020 | 40 | 8 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
| Nuo Therapeutics | 9 |
Brainstorm Cell Therapeutics News
- 2 months ago - Brainstorm Cell Therapeutics outlines readiness for Phase IIIb ALS trial as funding and regulatory developments shape next steps - Seeking Alpha
- 2 months ago - Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BrainStorm Cell Therapeutics GAAP EPS of -$0.77 - Seeking Alpha
- 2 months ago - BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics Q2 2025 Earnings Preview - Seeking Alpha
- 2 months ago - A Peek at Brainstorm Cell's Future Earnings - Benzinga
- 2 months ago - BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update - PRNewsWire
- 3 months ago - Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - Benzinga